Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adalimumab-aaty
- Development stage
- Approved
- Lead developer
- Celltrion
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Adalimumab-aaty is a biosimilar of adalimumab, marketed under the brand name Yuflyma. It is a fully human IgG1 monoclonal antibody that acts as a tumor necrosis factor (TNF) blocker. By binding specifically to TNF-alpha, it neutralizes its bioactivity and prevents interaction with cell surface TNF receptors, thereby reducing inflammation and immune activity. Adalimumab-aaty is indicated for the treatment of moderate to severe rheumatoid arthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis (in children 2 years and older), psoriatic arthritis, Crohn's disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious intermediate/posterior/panuveitis[1][3][5]. It may be used alone or in combination with other medications such as methotrexate.
- Brand names
- Yuflyma
- Other names
- adalimumab-aaty
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on adalimumab-aaty.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adalimumab-aaty.